Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price trimmed by Sanford C. Bernstein from $27.00 to $24 ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, ...

Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...